Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
PLSE · against 287 other Healthcare companies of similar size
Ranked #220 of 288 · scores higher than 3% of peers
Bars: peers in each 10-point band of the valuation score69 peers with a valuation score of 0–9, including PLSE · Click a bar to see the companies
Mainly because of its EBITDA yield and earnings yield, which are weaker than most Healthcare peers.
| Metric | PLSE | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 284 reported | -2.2% | 2.5% | 25% | 30% | |
| EBITDA yieldHigher is better · 283 reported | -2.3% | 4.7% | 18% | 50% | |
| Free cash flow yieldHigher is better · 151 reported | -1.6% | 0.9% | 39% | 20% | |
| Book yieldHigher is better · 282 reported | 2.7% | 28.4% | 6% | Context only |
| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 21.3B HKD (≈$2.7B) | 99 | 68 | |
| 1 | 52.2B HKD (≈$6.7B) | 99 | 56 | |
| 1 | 37.3B HKD (≈$4.8B) | 99 | 90 | |
| 1 | 40.2B MXN (≈$2.2B) | 99 | 71 | |
| 5 | 21.1B HKD (≈$2.7B) | 98 | 67 | |
| 220 | 2.3B USD | 8 | 26 | |
| 220 | 6.6B USD | 8 | 45 | |
| 220 | 1.9B USD | 8 | 32 | |
| 220 | 2.4B USD | 8 | ||
| 220 | 3.7B USD | 8 | 24 | |
| 220 | 2.4B USD | 8 | 20 | |
| 220 | 1.9B USD | 8 | 18 | |
| 220 | 3.8B USD | 8 | 48 | |
| 220 | 2.0B USD | 8 | 24 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score